Published in Lancet on May 16, 2012
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | NCT03104335
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol (2015) 2.19
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest (2013) 2.03
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer (2016) 1.44
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med (2017) 1.44
Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer (2013) 1.39
Presentation and management of pulmonary artery sarcoma. Clin Sarcoma Res (2015) 1.28
Malignant peripheral nerve sheath tumors. Oncologist (2014) 1.23
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol (2013) 1.18
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer (2012) 1.15
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist (2015) 1.13
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res (2015) 1.12
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
Brain metastasis in bone and soft tissue cancers: a review of incidence, interventions, and outcomes. Sarcoma (2014) 1.10
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer (2013) 1.05
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer (2015) 1.04
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis (2015) 1.02
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice. PLoS One (2015) 1.02
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell (2014) 1.01
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol (2014) 1.00
Advances in the targeted therapy of liposarcoma. Onco Targets Ther (2015) 0.99
Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res (2014) 0.99
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs (2015) 0.95
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol (2015) 0.95
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. Eur J Nucl Med Mol Imaging (2015) 0.93
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel) (2016) 0.91
Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas. Int J Gynecol Cancer (2014) 0.91
Pazopanib-Induced Severe Acute Pancreatitis. Case Rep Oncol (2015) 0.91
Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol (2014) 0.90
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer (2013) 0.90
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Current and future options in the management and treatment of uterine sarcoma. Ther Adv Med Oncol (2014) 0.90
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2015) 0.89
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer (2014) 0.88
Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res (2014) 0.88
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology network. Sarcoma (2014) 0.88
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs (2014) 0.87
Trabectedin in soft tissue sarcomas. Mar Drugs (2015) 0.87
Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res (2013) 0.87
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol (2016) 0.87
Dysphonia induced by anti-angiogenic compounds. Invest New Drugs (2013) 0.86
Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options. BMC Cancer (2015) 0.86
Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. J Cancer (2016) 0.86
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
Pazopanib and the treatment palette for soft-tissue sarcoma. Lancet (2012) 0.85
Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol (2013) 0.85
Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. Clin Sarcoma Res (2014) 0.85
Oligometastases/Oligo-recurrence of lung cancer. Pulm Med (2013) 0.85
Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. J Gastrointest Oncol (2016) 0.84
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer Chemother Pharmacol (2015) 0.84
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. Sarcoma (2016) 0.84
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors (2015) 0.84
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep (2014) 0.83
Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol (2015) 0.83
Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One (2014) 0.83
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res (2013) 0.83
Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies. Semin Oncol (2015) 0.83
Systemic therapy for selected skull base sarcomas: Chondrosarcoma, chordoma, giant cell tumour and solitary fibrous tumour/hemangiopericytoma. Rep Pract Oncol Radiother (2016) 0.83
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther (2013) 0.82
Primary Intimal Sarcoma of the Left Atrium: An Incidental Finding on Routine Echocardiography. Rare Tumors (2016) 0.82
A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer (2014) 0.82
Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clin Sarcoma Res (2015) 0.82
The off-label use of targeted therapies in sarcomas: the OUTC'S program. BMC Cancer (2014) 0.82
Targeted therapy for sarcomas. Biologics (2014) 0.82
Next generation sequencing in synovial sarcoma reveals novel gene mutations. Oncotarget (2015) 0.82
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clin Sarcoma Res (2014) 0.82
Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma. BMC Cancer (2014) 0.82
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy. Oncotarget (2014) 0.81
Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol (2012) 0.81
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. Clin Sarcoma Res (2015) 0.81
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer (2015) 0.81
A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer (2015) 0.81
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco Targets Ther (2014) 0.81
Targeted therapies: pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. Nat Rev Clin Oncol (2012) 0.81
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. Invest New Drugs (2013) 0.81
Malignant granular cell tumor of the back: a case report and review of the literature. Case Rep Med (2014) 0.81
Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma (2013) 0.81
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget (2015) 0.81
New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib. Clin Cancer Res (2014) 0.80
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Invest New Drugs (2012) 0.80
New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res (2012) 0.80
Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol Oncol (2014) 0.80
Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Front Oncol (2015) 0.80
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol (2014) 0.80
New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol (2012) 0.80
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer (2014) 0.80
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol (2015) 0.80
Potential for immunotherapy in soft tissue sarcoma. Hum Vaccin Immunother (2014) 0.80
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. Oncol Lett (2016) 0.80
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer (2014) 0.80
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br J Cancer (2015) 0.80
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer (2013) 0.80
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian J Med Paediatr Oncol (2016) 0.80
Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report. BMC Res Notes (2014) 0.79
More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomark Insights (2015) 0.79
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol (2010) 7.70
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol (2008) 6.43
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA (2012) 5.00
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med (2006) 4.52
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol (2011) 4.19
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes. Science (2006) 3.87
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet (2010) 3.78
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol (2013) 3.67
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology (2004) 3.61
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol (2009) 3.53
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 3.35
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol (2007) 3.35
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Gastrointestinal stromal tumour. Lancet (2013) 3.19
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol (2004) 3.10
Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology (2003) 3.08
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer (2011) 2.95
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer (2014) 2.94
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res (2004) 2.90
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol (2008) 2.85
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol (2002) 2.85
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol (2010) 2.74
Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting. J Thorac Oncol (2015) 2.68